The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular ...

The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.

Humacyte, Inc. announced that the FDA has granted full approval for the company’s Symvess—acellular tissue enginee ...

A Durham company secured federal approval for its bioengineered tissue, which could become a revolutionary treatment for ...

Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair ...

As of Friday’s premarket trading session, Humacyte’s stock surged +33.52% to $4.62, reflecting investor optimism following this groundbreaking news. While the company’s stock has had a solid +21.83% ...

Highlights,FDA approves SYMVESS for urgent arterial injury treatment.,Clinical trials show high patency and low complication ...

SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

Varicose veins require thorough assessment by vascular surgeons, especially using ultrasound, to determine the underlying ...

Millions of Americans suffer from vein disease and it’s not just a cosmetic issue. To better understand vein disease and what ...

Discover expert advice on vein health and treatment options from Ozark Regional Vein and Artery Center. Sponsored segment ...